Current Report Filing (8-k)
February 20 2020 - 6:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM 8-K
___________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
February 19, 2020
CELLECTAR BIOSCIENCES, INC.
(Exact name of registrant as specified in charter)
Delaware
|
1-36598
|
04-3321804
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
100 Campus Drive, Florham Park, New Jersey
07932
(Address of principal executive offices, and zip code)
(608) 441-8120
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common stock, par value $0.00001
|
|
CLRB
|
|
NASDAQ Capital Market
|
|
|
|
|
|
Warrant to purchase common stock, expiring
April 20, 2021
|
|
CLRBZ
|
|
NASDAQ Capital Market
|
ITEM 7.01
|
REGULATION FD DISCLOSURE
|
On February 19, 2020, we held a CLR 131 clinical data call reporting
positive data from our Phase 2 CLOVER-1 study in patients with relapsed/refractory B-cell lymphomas.
A copy of the clinical data call presentation is furnished as Exhibit 99.1 and is incorporated by reference herein.
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS
|
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 19, 2020
|
CELLECTAR BIOSCIENCES, INC.
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Dov Elefant
|
|
|
|
Name:
|
Dov Elefant
|
|
|
Title:
|
Chief Financial Officer
|
|
|
|
|
|
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Apr 2023 to Apr 2024